There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Nichi-Iko Pitting Allegra AG against Other Generics, Not Originator: Pres. Tamura
November 8, 2013
-
REGULATORY “Precursor Premium” Proposed at CSIMC Drug Pricing Subcommittee, Yet Further Deliberations Necessary
November 7, 2013
-
REGULATORY Chairman Eto of LDP’s Study Group on Drug Industry Policy Calls for “Balance” in Discussions of Special Price Cuts for Long-Listed Drugs
November 7, 2013
-
BUSINESS Japan ARB Market Gets Back on Growth Track in April-September; No Major Impact from Diovan Woes
November 6, 2013
-
ORGANIZATION Drug Damage Watchdog Presses Criminal Charge against Novartis over Diovan Ads
November 5, 2013
-
ACADEMIA Subordinate of Former Employee of Novartis Pharma Participated in SMART Study; Protocol Violations Also Found
November 5, 2013
-
ACADEMIA Mismatch Found for 10% of ACR Data Between Papers, Patient Records: SMART Study
November 1, 2013
-
BUSINESS Takeda 1st Half Sales Rise 5.3% on New Portfolio, Weaker Yen
November 1, 2013
-
REGULATORY New CSIMC Healthcare Rep Nakagawa Says Against Perpetuation of Premium
October 31, 2013
-
ORGANIZATION PhRMA Makes Yet Another Case for Perpetuation of New Drug Premium
October 31, 2013
-
REGULATORY Generic Use for Anti-Allergic Agents Jumps after Pilot Leaflet Project: Kyokai Kenpo
October 30, 2013
-
REGULATORY 1st Committee Backs Japan Tobacco’s Hyperphosphatemia Treatment
October 30, 2013
-
ACADEMIA Beta Blockers “Inferior to Other Drugs,” Will Not Be Recommended as 1st–Line Treatments in New Hypertension GL
October 29, 2013
-
ORGANIZATION Generic Makers to Jointly Outsource GMP Inspections on Drug Substance Suppliers; Pilot to Begin by March
October 28, 2013
-
BUSINESS Teva’s Global Medical Director Says Biosimilars Can Cut Medical Costs
October 25, 2013
-
REGULATORY Regulatory Reform Council to Convene Public Discussion on Expansion of “Mixed Healthcare” on November 28
October 25, 2013
-
REGULATORY Diovan Panel Should Question 4 Key Figures to Dig into Scandal Further: Expert Member
October 24, 2013
-
REGULATORY MOF Demands Hefty Price Cuts for Long-Listed Products, Skeptical about Premium
October 23, 2013
-
BUSINESS Swiss Novartis Sees 22% Plunge in January-September Diovan Sales
October 23, 2013
-
ORGANIZATION No Clear Violation of Fair Competition Code in Diovan Case: Maker FTC Exec
October 22, 2013
ページ
Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…